Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT04136184 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04136184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04136184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 11, 2019
Completion date
July 12, 2023
Enrollment
168 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary transthyretin-mediated amyloid polyneuropathy